CompoundAtlas
Sign in

Tirzepatide

81
evidence score
fat loss
Prescription Only
185 studies
MounjaroZepboundLY3298176+1 more

Tirzepatide is a once-weekly injectable dual agonist of GLP-1 and GIP receptors, approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. In the SURMOUNT trials, tirzepatide 15mg produced ~22.5% average weight loss over 72 weeks — the greatest pharmacological weight reduction ever demonstrated in a pivotal trial. GIP agonism adds metabolic benefits beyond GLP-1 alone, including adipocyte sensitization and muscle preservation. Superior efficacy vs. semaglutide in head-to-head trials (SURPASS-2).

Evidence

Strong evidence

Safety

Unknown safety profile

Clinical Status

Approved

Last Sync

Feb 19, 2026

Last Reviewed

Not reviewed yet

Physician Notes

Microdose and go slow. Compounded tirzepatide allows flexible dosing. Stack with sermorelin for muscle preservation.

FDA Status:FDA-approved as Mounjaro (diabetes) and Zepbound (obesity).

Monitoring

  • HbA1c/fasting glucose q3mo
  • Weight + body composition q3mo
  • Lipid panel q6mo
  • GI symptom assessment

Contraindications

  • Personal/family history of medullary thyroid carcinoma
  • MEN2 syndrome
  • Pancreatitis history (relative)
Velix Health

Want this prescribed by a board-certified physician?

Velix Health physicians review your labs, build evidence-based protocols, and monitor your progress. Every prescription is referenced.

Apply for Membership

Dosing

Typical
10 mg
2.5 mgRange15 mg
FrequencyOnce weekly subcutaneous

Set height & weight in Settings to see your dose.

Pharmacology

Half-life~5 days
OnsetAppetite suppression within days; full effect over months
DurationOngoing; weight regain begins within weeks of stopping
Routes
subcutaneous

Evidence Score

81
Level A — Strong
185 studies indexed · 18 meta-analyses
Scoring Factors
Volume(24%)~45/100
Quality(24%)~59/100
Sample Size(12%)~100/100
Consistency(14%)~100/100
Replication(8%)~100/100
Recency(18%)~100/100

Scores estimated from study counts. Exact breakdown computed after research sync.

Evidence Levels
AScore ≥75 with at least 1 meta-analysis and 3+ RCTs
BScore ≥50 with at least 1 RCT or meta-analysis
CScore ≥25 — observational or animal evidence only
DScore <25 — very limited or preclinical data

Plain-English Snapshot

Tirzepatide is currently categorized as a fat loss compound.

Evidence is strong (81/100) with a relatively mature body of research (185 indexed studies).

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

Dual GLP-1/GIP receptor agonist; GIP agonism sensitizes adipocytes and augments incretin effect beyond GLP-1 alone

Practical Context

Strongest current signals

  • Level B: People With Lowest Physical Functioning Scores Showed Greatest Improvement After Tirzepatide Treatment.
  • Level B: Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial.
  • Level B: Association of baseline characteristics with clinical outcomes of tirzepatide treatment in Japanese patients with obesity disease: A subgroup analysis of the SURMOUNT-J trial.

Elevated caution signals

2 severe/high side effect flags

Compound Profile